What is HC Wainwright’s Estimate for KPRX FY2024 Earnings?

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) – Stock analysts at HC Wainwright cut their FY2024 EPS estimates for shares of Kiora Pharmaceuticals in a research note issued to investors on Monday, November 11th. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings per share of $1.28 for the year, down from their prior forecast of $1.58. HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for Kiora Pharmaceuticals’ current full-year earnings is $1.17 per share. HC Wainwright also issued estimates for Kiora Pharmaceuticals’ Q4 2024 earnings at ($0.74) EPS, Q1 2025 earnings at $0.67 EPS and FY2025 earnings at ($2.76) EPS.

Kiora Pharmaceuticals (NASDAQ:KPRX) last issued its earnings results on Friday, November 8th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.90) by $0.09.

Kiora Pharmaceuticals Price Performance

NASDAQ KPRX opened at $3.40 on Thursday. Kiora Pharmaceuticals has a 1-year low of $3.00 and a 1-year high of $8.98. The business’s fifty day moving average price is $3.52 and its 200-day moving average price is $4.28.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Kiora Pharmaceuticals stock. Stonepine Capital Management LLC purchased a new stake in shares of Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 200,000 shares of the company’s stock, valued at approximately $840,000. Kiora Pharmaceuticals comprises about 0.8% of Stonepine Capital Management LLC’s investment portfolio, making the stock its 16th biggest holding. Stonepine Capital Management LLC owned approximately 6.86% of Kiora Pharmaceuticals as of its most recent filing with the SEC. 76.97% of the stock is owned by institutional investors and hedge funds.

Kiora Pharmaceuticals Company Profile

Kiora Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.